Skip to main content
SpringerLink
Log in

Metastasiertes Mammakarzinom

Biologisch stratifizierte Therapie

  • Zertifizierte Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Zusammenfassung

Das metastasierte Mammakarzinom verläuft chronisch-progredient und ist nicht mehr heilbar. Primäres Behandlungsziel ist es, Metastasen-bedingte Beschwerden zu lindern und die Lebensqualität zu erhalten. Für die Therapieentscheidung sind patientenbezogene Aspekte wie etwa das Alter relevant, aber auch krankheitsabhängige Faktoren wie der Rezeptorstatus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Robert Koch Institut. http://www.rki.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html. Letzter Zugriff: 20.08.2014.

  2. Berry DA et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92.

    Article  CAS  PubMed  Google Scholar 

  3. O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncol. 2005;10(3):20–29.

    Article  Google Scholar 

  4. Amir E et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30(6):587–92.

    Article  PubMed  Google Scholar 

  5. Nabholtz JM et al. Anastozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18(22):3758–67.

    CAS  PubMed  Google Scholar 

  6. Mouridsen H et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;9(19):2596–606.

    Google Scholar 

  7. Howell A et al. Fulvestrant, formerly ICI182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20(16): 3396–3403.

    Article  CAS  PubMed  Google Scholar 

  8. Robertson JFR et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‚FIRST“ study. Breast Cancer Res Treat. 2012; 136(2):503–11.

    Article  CAS  PubMed  Google Scholar 

  9. Baselga J et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.

    Article  CAS  PubMed  Google Scholar 

  10. Finn RS et al. Final Results of a Randomized Phase 2 Study of Palbociclib (PD 0332991) a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in combination with Letrozole vs Letrozole Alone for First-Line Treatment of ER+, HER2-Advanced Breast Cancer (PALOMA-1/TRIO-18). AACR. 2014;Abstr CT101.

    Google Scholar 

  11. Finn RS et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5): R77.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Hudis CA. Trastuzumab - Mechanism of action and use in clinical Practice. N Engl J Med. 2007;357(1):39–51.

    Article  CAS  PubMed  Google Scholar 

  13. Marty M et al. Randomized phase II trial of the efficacy and safety of trastzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positiv metastastic breast cancer administerd as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–74.

    Article  CAS  PubMed  Google Scholar 

  14. Scheuer W et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330–6.

    Article  CAS  PubMed  Google Scholar 

  15. Nahta R et al. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343–6.

    Article  CAS  PubMed  Google Scholar 

  16. Johnston S et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.

    Article  CAS  PubMed  Google Scholar 

  17. Lin NU et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–9.

    Article  CAS  PubMed  Google Scholar 

  18. Baselga J et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.

    Article  CAS  PubMed  Google Scholar 

  19. Swain SM et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Verma S et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.

    Article  CAS  PubMed  Google Scholar 

  21. Kaufman B et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37.

    Article  CAS  PubMed  Google Scholar 

  22. Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76.

    Article  CAS  PubMed  Google Scholar 

  23. Robert NJ et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252–60.

    Article  CAS  PubMed  Google Scholar 

  24. O’Shaughnessy J et al. Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2011;364(3):205–14.

    Article  PubMed  Google Scholar 

  25. O’Shaughnessy J et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol. 2011;29(suppl):Abstr 1007.

    Google Scholar 

  26. Anders C et al. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2014;146(3):557–66.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Isabel Sicking

  2. Klinik und Poliklinik für Geburtshilfe und Frauenkrankheiten, Universitätsmedizin Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland

    Marcus Schmidt

Authors
  1. Isabel Sicking
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcus Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcus Schmidt.

Additional information

Interessenkonflikt

PD Dr. Marcus Schmidt gibt Beratungs- und Vortragstägikeiten für Roche, Novartis, Pfizer, Astra-Zeneca, Sanofi und GlaxoSmithKline an. Dr. Isabel Sicking gibt keine potenziellen Interessenkonflikte an.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheits bildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sicking, I., Schmidt, M. Biologisch stratifizierte Therapie. Im Focus Onkologie 17, 46–52 (2014). https://doi.org/10.1007/s15015-014-0011-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-0011-y

Search

Navigation